Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study

Prathibha V K; Mukundan C; Bhagyalekshmi N

doi:10.5455/njppp.2020.10.04081202004042020

2026, Vol: 16, Issue: 2

16 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 14 Apr 2020

Natl J Physiol Pharm Pharmacol. 2020; 10(5): 423-430

doi: 10.5455/njppp.2020.10.04081202004042020

Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study

Prathibha V K, Mukundan C, Bhagyalekshmi N.

Cited By:1

Abstract
Background: Altered hemodynamics of heart failure patients is associated with an increased heart rate (HR). The effect of β-blockers on prognosis has been linked to their HR lowering effect. Ivabradine is an If current inhibitor and it decreases the heart rate.

Aims and Objectives: The aim of this study was to compare the efficacy of ivabradine, a combination of ivabradine and metoprolol, with that of metoprolol alone in patients with heart failure.

Materials and Methods: This prospective observational study was done in patients with New York Heart Association (NYHA) Class III/IV heart failure over 18 months. Patients were categorized into Group A: Ivabradine (5 mg BD), Group B: Metoprolol (12.5 mg BD), and Group C: Combination of both (5 mg BD and 12.5 mg BD). At the end of 6 months follow-up, the outcomes of therapy were assessed based on the occurrence of major adverse cardiac events (MACE) such as acute coronary syndrome, rehospitalization, or death. Effectiveness was also measured in terms of a decrease in HR, improvement in left ventricular ejection fraction (LVEF), and NYHA functional class.

Results: One hundred and fifty-two patients were included in this study in three groups 51 patients in Group A, 50 patients in Group B, and 51 patients in Group C. At the end of follow-up period, it was found that the highest number of MACE occurred in Group B followed by A and C. Group C showed significant improvement with therapy in terms of decrease in HR, increase in LVEF, and improvement in NYHA class.

Conclusion: Administration of ivabradine alone or a combination of ivabradine and metoprolol is more effective than metoprolol in reducing the incidence of MACE in heart failure.

Key words: Heart Failure; Heart Rate; Ivabradine; Metoprolol; Major Adverse Cardiac Events; New York Heart Association class

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Prathibha V K Articles by Mukundan C Articles by Bhagyalekshmi N
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol. 2020; 10(5): 423-430.

doi:10.5455/njppp.2020.10.04081202004042020

Web Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. https://www.njppp.com/?mno=96255 [Access: June 27, 2026].

doi:10.5455/njppp.2020.10.04081202004042020

AMA (American Medical Association) Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol. 2020; 10(5): 423-430.

doi:10.5455/njppp.2020.10.04081202004042020

Vancouver/ICMJE Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol. (2020), [cited June 27, 2026]; 10(5): 423-430.

doi:10.5455/njppp.2020.10.04081202004042020

Harvard Style

K, P. V., C, . M. & N, . B. (2020) Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol, 10 (5), 423-430.

doi:10.5455/njppp.2020.10.04081202004042020

Turabian Style

K, Prathibha V, Mukundan C, and Bhagyalekshmi N. 2020. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. National Journal of Physiology, Pharmacy and Pharmacology, 10 (5), 423-430.

doi:10.5455/njppp.2020.10.04081202004042020

Chicago Style

K, Prathibha V, Mukundan C, and Bhagyalekshmi N. "Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study." National Journal of Physiology, Pharmacy and Pharmacology 10 (2020), 423-430.

doi:10.5455/njppp.2020.10.04081202004042020

MLA (The Modern Language Association) Style

doi:10.5455/njppp.2020.10.04081202004042020

APA (American Psychological Association) Style

doi:10.5455/njppp.2020.10.04081202004042020

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article